Volatile Stock to Watch: BioPharmX Corporation (NYSE:BPMX)

US stocks swung into the black in early afternoon trade as investors weighed the minutes of Federal Reserve’s most recent meeting, which suggested policymakers would push through further rate rises, against comments a day earlier from the central bank’s chairman that rates were close to being on an even keel.

The minutes from the Fed’s November meeting showed almost all of its policymakers said at the time they expected to proceed with further gradual increases in interest rates if the US economy remains on track. The bank is expected to pull the trigger in December on its fourth and final interest rate rise for the year.

But Fed watchers were given fresher food for thought on Wednesday when Fed chairman Jay Powell said in prepared remarks that interest rates were “just below” neutral, a level regarded as neither helping nor hindering economic growth.

Mr Powell’s comments were interpreted by the market at the time as dovish and spurred a strong rally that yesterday handed the S&P 500 its biggest one-day gain since March.

Stocks were in pullback mode from the open on Thursday and the main equities gauges were down between 0.1 per cent and 0.2 per cent ahead of the release of the minutes.

About 15 minutes after the release, stocks had trimmed their decline, with the S&P 500 and Nasdaq Composite each up 0.1 per cent and the Dow Jones Industrial Average flat.

Treasuries remained mixed, with the longer-dated notes and bonds slightly firmer as yields fell. The yield on the benchmark 10-year US Treasury was down 0.9 basis points at 3.0352 per cent, while that on the more policy-sensitive two-year was up 2 bps to 2.8066 per cent.

Earlier today the 10-year yield fell below 3 per cent for the first time since mid-September.

The dollar held firm, with the DXY Index remaining 0.1 per cent higher at 96.854.

Shares of BioPharmX Corporation (NYSE:BPMX) flaunted a rapid change of 0.90% to reach at $0.17 in the last hour of Thursday’s trading session. The company has experienced volume of 1,600,780 shares while on average the company has a capacity of trading 3.66M share.

BioPharmX Corporation (BPMX) holds the market capitalization of $32.16M along with 191.33M outstanding shares. The stock price is moving -68.10% off from the highest level of twelve months and -55.19% above from twelve months low. For the stock, price target value has been calculated at $1.05.

What Historical Figures Say About Synthetic Biologics (NYSE: BPMX)?

Before trading, trader, investor or shareholder must have an eye on stock’s historical performance. Analysts review historical return data when trying to predict future returns or to estimate how a security might react to a particular situation, such as a drop in consumer demand. Historical returns can also be useful when estimating where future points of data may fall in terms of standard deviations.

Analyzing historical data can give some perception of how a security or market has reacted to various different variables, from regular economic cycles to sudden world events. Shareholders looking to interpret historical returns should keep one caveat in mind: you can’t assume that the future will be like the past. The older the historical return data is, the more likely it is to be less useful when predicting future returns. Historical return data for BPMX stock is described below:

BioPharmX Corporation has shown weekly performance of 1.88%. Its six months performance -37.23% indicated a movement while its yearly performance reflected a trend of 33.73%. Year-to-date (YTD) performance of the stock illustrate trend of 52.54%. The company has Relative Strength Index (RSI 14) of 42.37 along with Average True Range (ATR 14) of 0.01. Its weekly and monthly volatility is 4.44%, 6.03% respectively. The company’s beta value is at -0.39.

What is PEG Ratio?

PEG ratio or Price/Earnings-Growth ratio is an attempt to normalize the P/E ratio with the expected earnings growth rate of the company.

The idea behind the PEG ratio for stocks is quite simple:

A low P/E ratio can be justified if the future expected earnings growth is low. A fast growing company on the other hand is able to command a higher price to earnings multiple for its stock. To get more accurate idea of the relative valuation of a company, we need to consider the P/E ratio in conjunction with the future earnings per share growth rate.

WHY IT MATTERS:

The PEG ratio acts as a measure of value that takes into account future growth. Using this metric, investors can gauge whether high-growth stocks may be undervalued, even if they don’t appear so with the more common P/E ratio.

Earnings growth expectations are completely unreliable. Any use of the formula is only as good as the numbers that are fed into it as inputs. Any expected earnings growth in the future is just an expectation, and they vary wildly between different analysts. Even if there is a concensus, the future generally turns out to be different than planned. There is competitive changes, loss of market power, product substitutions, management missteps, etc, that we have no way of knowing today.

Typically P/E ratios are backward looking while the earnings growth rate is a forward looking metric. Future P/E ratio will be different than the one we use today. You could project a future P/E ratio if you wish, but this will introduce further uncertainity in the calculations. Still, many investors are fond of using the concept of Forward P/E and Forward PEG ratio. I strongly advise against this.

Negative PEG Ratio Meaning

A negative PEG ratio does not imply that the stock is a bad investment. It just means that you need to consider other ways of looking at the stock before you can judge if this is a good investment or not.

Is It Overvalued? Look at the PEG Ratio

BioPharmX Corporation (NYSE:BPMX) currently has a PEG ratio of N/A where as its P/E ratio is N/A. The company’s price to sales ratio for trailing twelve months is 407.11 and price to book ratio for most recent quarter is 8.40, whereas price to cash per share for the most recent quarter is 4.87. BPMX’s price to free cash flow for trailing twelve months is N/A. Its quick ratio for most recent quarter is 2.40 along with current ratio for most recent quarter of 2.40. Total debt to equity ratio of the company for most recent quarter is 0.00 whereas long term debt to equity ratio for most recent quarter is 0.00. BioPharmX Corporation has a Return on Assets of -221.90%. The company currently has a Return on Equity of -443.50% and Return on Investment of N/A.

Leave a Comment

Your email address will not be published. Required fields are marked *